Strand Life Sciences provides bioinformatics solutions with advanced visualization, predictive systems modeling, data integration, and scientific context management components to transform raw data into actionable insights. The company employs 200 people, mostly in Bangalore, India, and services both the research and clinical markets. 

Strand enjoys three advantages over the competition globally: superior software analytics, superior curation of gene variants, and a major cost advantage for DNA test interpretation. When combined, Strand is finding a rapidly growing demand for its StrandOmics software platform, which hospitals and service providers can use to service their patients and healthcare clients. With every sequence and gene test, the company’s cloud database gets more valuable with related metadata, which can be used to improve future analytics, thereby creating an additional demand for StrandOmics.

Strand has developed the most advanced software for analyzing DNA sequences. Today, 1,400 research institutions worldwide use Strand’s software under the product names GeneSpring (marketed by Agilent) and Avadis (marketed by Strand). The company reached profitability in 2007, and in early 2013, the company began to service the clinical market in India. It opened its own DNA sequence and gene panel wet lab in Bangalore, India, and in December, the company opened a lab which it operates in the 1,400-bed Mazumdar-Shaw Cancer Center in Bangalore. By the end of 2013, Strand was servicing the gene testing and DNA sequence analysis needs of over 100 hospitals in India, and in 2014 it has begun to expand into the US market.